Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer

Isamu Okamoto, Kazuhiko Fujii, Mitsuhiro Matsumoto, Yasuhiro Terasaki, Nanae Kihara, Hirotsugu Kohrogi, Moritaka Suga

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

ZD1839 is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). We now present a case of diffuse alveolar damage (DAD) that developed in a 67-year-old man treated with ZD1839. On day 8 of ZD1839 administration, the patient complained of dyspnea and a new-ground glass opacity was apparent on a chest X-ray and computed tomography scan. Despite high-dose steroid therapy, the patient died 13 days after the first administration of ZD1839. Postmortem analysis of lung tissue revealed a pattern of DAD. No evidence of infection or of other specific etiologies was apparent. This case is the first reported of respiratory failure after ZD1839 treatment in a patient with NSCLC. Physicians should therefore be aware of the potential pulmonary toxicity of ZD1839.

Original languageEnglish
Pages (from-to)339-342
Number of pages4
JournalLung Cancer
Volume40
Issue number3
DOIs
Publication statusPublished - Jun 1 2003
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Okamoto, I., Fujii, K., Matsumoto, M., Terasaki, Y., Kihara, N., Kohrogi, H., & Suga, M. (2003). Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer, 40(3), 339-342. https://doi.org/10.1016/S0169-5002(03)00043-6